Filing Analysis
Apyx Medical Corporation reported the results of its 2026 Annual Meeting of Stockholders held on August 6, 2026. The meeting included the election of five directors and the approval of several key shareholder proposals.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The Company's stockholders elected five directors: Stavros G. Vizirgianakis, Charles D. Goodwin, Lawrence J. Waldman, Minnie Baylor-Henry, and Wendy Levine.
- Stockholders ratified RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- A non-binding advisory resolution supporting executive compensation was approved.
- The 2026 Share Incentive Plan was approved by stockholders.
Apyx Medical Corp filed an 8-K to announce its second quarter 2026 results of operations via a press release. The filing is a standard earnings announcement under Item 2.02.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 6, 2026.
- The company issued an earnings press release (Exhibit 99.1) to disclose financial results.
Apyx Medical Corporation announced the reconstitution of its standing committees on July 24, 2026. This includes changes to committee memberships and chairs following Stavros Vizirgianakis's appointment as Executive Chairman.
📋 Key Facts
- Board reconstituted Audit, Governance and Nominating, Regulatory Compliance, and Compensation committees.
- Stavros Vizirgianakis will no longer serve on any committee due to his role as Executive Chairman (effective June 11, 2026).
- Lawrence J. Waldman appointed as Chair of the Audit Committee and is designated as an 'audit committee financial expert'.
- Minnie Baylor-Henry appointed as Chair of Governance and Nominating and Regulatory Compliance committees.
- Wendy Levine appointed as Chair of the Compensation Committee.
Apyx Medical Corp entered into a letter agreement on June 11, 2026, appointing Stavros Vizirgianakis as Executive Chairman of the Board. In connection with this role, Mr. Vizirgianakis was granted 450,000 restricted stock units (RSUs) with a tiered vesting schedule.
🚩 Red Flags
- Related-party transaction: Significant equity grant to the Chairman of the Board.
- Immediate vesting of 150,000 RSUs (one-third of the total grant) upon appointment.
📋 Key Facts
- Appointment of Stavros Vizirgianakis as Executive Chairman effective June 11, 2026.
- Grant of 450,000 restricted stock units (RSUs) under the 2023 Share Incentive Plan.
- Vesting schedule: 150,000 RSUs vested immediately on June 11, 2026; 150,000 RSUs vest ratably over 12 months starting June 11, 2027; 150,000 RSUs vest ratably over 12 months starting June 11, 2028.
- Mr. Vizirgianakis will not be designated as an 'executive officer' per Rule 3b-7 of the Exchange Act.
Apyx Medical Corporation announced the publication of new clinical data in the Aesthetic Surgery Journal Open Forum. The study highlights a promising approach to treating cellulite and skin laxity, two common aesthetic concerns, using the company's technology.
📋 Key Facts
- Filing date: May 21, 2026
- The clinical data was published in the peer-reviewed Aesthetic Surgery Journal Open Forum
- The study focuses on improving cellulite and skin laxity
- The announcement was made via a press release attached as Exhibit 99.1
Apyx Medical Corporation announced the publication of a retrospective investigator-initiated study in a peer-reviewed medical journal. The study evaluated patient-reported outcomes for the company's Renuvion product when used in conjunction with liposuction.
📋 Key Facts
- The study was published in 'Plastic and Reconstructive Surgery - Global Open' on May 14, 2026.
- The research compared outcomes of liposuction alone versus liposuction combined with helium plasma radiofrequency (Renuvion).
- The study is categorized as a retrospective investigator-initiated study, which typically carries less weight than prospective, company-sponsored pivotal trials.
- The filing was made under Item 8.01 (Other Events).
Apyx Medical Corporation announced it has received expanded 510(k) clearance from the U.S. FDA for its AYON Body Contouring System. The expanded clearance specifically allows the system to include power liposuction capabilities.
📋 Key Facts
- On May 11, 2026, the company received expanded 510(k) clearance from the FDA.
- The clearance pertains to the AYON Body Contouring System.
- The expansion adds power liposuction to the system's cleared indications for use.
Apyx Medical Corporation furnished its first quarter 2026 financial results via a press release on May 7, 2026. The filing covers the three-month period ended March 31, 2026.
📋 Key Facts
- Earnings release for Q1 ended March 31, 2026
- Filed under Item 2.02 (Results of Operations and Financial Condition)
- Press release included as Exhibit 99.1
- Matthew Hill, CFO, signed the filing
Apyx Medical Corporation reported its financial results for the fourth quarter and full year ended December 31, 2025, via a press release on March 10, 2026.
📋 Key Facts
- The company reported results for the fourth quarter and fiscal year ended December 31, 2025
- The information was furnished under Item 2.02 Results of Operations and Financial Condition
- The full press release is included as Exhibit 99.1
- The filing was signed by Matthew Hill, Chief Financial Officer
Apyx Medical Corp issued an 8-K to furnish preliminary revenue results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal announcement of earnings performance via a press release.
📋 Key Facts
- Reported date: January 12, 2026
- Reporting period: Q4 and Full Year ended December 31, 2025
- Nature of report: Preliminary revenue results
- Exhibits include a press release (Exhibit 99.1) containing the financial data
Apyx Medical Corporation filed an 8-K to report the formal filing of a Certificate of Amendment with the State of Delaware. This amendment, previously approved by stockholders on August 7, 2025, involves the removal of Article EIGHTH from the Company's Certificate of Incorporation.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- The company filed a Certificate of Amendment to its Certificate of Incorporation on December 8, 2025.
- The amendment removes 'Article EIGHTH' in its entirety and replaces it with 'intentionally omitted'.
- The change was previously approved by stockholders during the Annual Meeting held on August 7, 2025.
- The filing is a formalization of a corporate governance change already disclosed in previous proxy statements.
Apyx Medical Corporation completed a public offering of 2,762,431 shares of common stock at $3.62 per share. The offering raised approximately $9.4 million in gross proceeds to be used for working capital and general corporate purposes.
🚩 Red Flags
- Equity dilution: Issuance of over 2.7 million new shares will dilute existing shareholders.
📋 Key Facts
- Offered 2,762,431 shares of common stock plus an option for up to 414,365 additional shares.
- Offering price set at $3.62 per share.
- Gross proceeds total approximately $9.4 million (before expenses and underwriting discount).
- Underwriting discount is 6.0% of the price to the public.
- The offering closed on November 19, 2025.
- Proceeds are earmarked for working capital, sales/marketing expansion, CapEx, acquisitions, and debt repayment.
Apyx Medical Corp filed an 8-K to announce its third quarter 2025 earnings results. The filing serves as a formal mechanism to furnish the quarterly press release via Item 2.02.
📋 Key Facts
- The company reported results of operations for the third quarter ended September 30, 2025.
- The announcement was made on November 6, 2025.
- Earnings press release is attached as Exhibit 99.1.
Apyx Medical Corp reported the results of its annual meeting of stockholders held on August 7, 2025. The filing details the election of five directors and the ratification of the company's independent auditor.
📋 Key Facts
- Five directors were elected: Stavros G. Vizirgianakis, Charles D. Goodwin, Lawrence J. Waldman, Minnie Baylor-Henry, and Wendy Levine.
- RSM US LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Stockholders approved a non-binding advisory resolution regarding executive compensation.
- Stockholders voted on the frequency of advisory votes on executive compensation, with 'One Year' receiving the majority (9,205,086 votes).
- An amendment to the Certificate of Incorporation to remove Article EIGHTH was approved.
Apyx Medical Corp issued an 8-K to announce its second quarter 2025 earnings results. The filing serves as a formal mechanism to furnish the quarterly press release under Item 2.02.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 7, 2025.
- The filing includes an earnings press release as Exhibit 99.1.
Apyx Medical Corp announced that it has received U.S. FDA clearance for its AYON Body Contouring System™. This is a regulatory milestone for the company's product pipeline.
📋 Key Facts
- FDA clearance received for the AYON Body Contouring System™ on May 13, 2025.
- The announcement was made via press release attached as Exhibit 99.1.
Apyx Medical Corp filed an 8-K to report its results of operations for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the quarterly earnings press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The company issued an earnings press release (Exhibit 99.1) regarding its financial condition and results of operations.
Apyx Medical Corp announced the publication of two peer-reviewed clinical studies regarding the use of its Renuvion® technology in body contouring procedures, specifically involving lipoabdominoplasty.
📋 Key Facts
- Published two peer-reviewed clinical studies on April 29, 2025.
- Studies evaluate the efficacy/use of Renuvion® during body contouring and lipoabdominoplasty procedures.
Apyx Medical Corp filed an 8-K to announce its results of operations for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of the earnings press release issued on March 13, 2025.
📋 Key Facts
- Reported results of operations for Q4 and FY 2024.
- Earnings press release issued on March 13, 2025 (Exhibit 99.1).
- Filed under Item 2.02 regarding Results of Operations and Financial Condition.
Apyx Medical Corp announced the employment agreement for Shawn Roman as Chief Operating Officer, effective January 28, 2025. The filing details his compensation structure including base salary and bonus potential.
📋 Key Facts
- Shawn Roman appointed as Chief Operating Officer (COO).
- Employment Agreement effective date: January 28, 2025.
- Initial annual base salary: $305,760.52.
- Target annual bonus: Not less than 50% of Base Salary, subject to achievement of objectives.
- Eligibility for equity-based incentive plans as determined by the Compensation Committee.
Apyx Medical Corp issued an 8-K to report preliminary revenue results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of the company's financial performance metrics via a press release.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Report date: January 13, 2025.
- Content: Preliminary revenue results provided via Exhibit 99.1.
Apyx Medical Corp announced the submission of a 510(k) premarket notification to the FDA for its AYON Body Contouring System. This represents a standard regulatory milestone in the product development lifecycle.
📋 Key Facts
- Submitted 510(k) premarket notification to the U.S. FDA on January 6, 2025.
- The submission is for the AYON Body Contouring System.
- Filing was made under Item 8.01 (Other Events).
Apyx Medical Corp announced a significant restructuring involving the resignation of three directors, the termination of its EVP of Sales and Marketing, and an amendment to its credit agreement. Simultaneously, the company closed a $7 million registered offering of common stock and pre-funded warrants to bolster working capital.
🚩 Red Flags
- Significant dilution via the issuance of 3 million shares and nearly 3 million pre-funded warrants.
- Multiple items in a single filing (Amendment to credit, securities offering, officer departures) indicating high corporate volatility.
- Reduction of revenue targets in credit agreement suggests downward revisions in financial expectations.
- Board size reduction from eight to five directors following multiple resignations.
📋 Key Facts
- Closed a Registered Offering on November 8, 2024, for approximately $7 million gross proceeds.
- Offered 3,000,000 shares at $1.18 per share and up to 2,934,690 pre-funded warrants at $1.179 per warrant.
- Amended Credit Agreement with Perceptive Credit Holdings IV, LP; includes new operating expense caps ($40M for FY2025; $45M for FY2026).
- Reduced Minimum Advanced Energy Net Revenue Targets through September 30, 2028.
- Three directors (John Andres, Michael Geraghty, and Craig Swandal) resigned effective November 4, 2024.
- Terminated EVP of Sales and Marketing Todd Hornsby without cause; responsibilities assumed by CEO Charlie Goodwin.
- Appointed Shawn Roman as Chief Operating Officer.
Apyx Medical Corp reported the final voting results from its annual meeting of stockholders held on August 8, 2024. The results included the election of eight directors and the ratification of RSM US LLP as the company's independent auditor.
📋 Key Facts
- Eight directors were elected to serve until the 2025 Annual Meeting: Stavros G. Vizirgianakis, Charles D. Goodwin, Michael Geraghty, Lawrence J. Waldman, John Andres, Craig Swandal, Minnie Baylor-Henry, and Wendy Levine.
- Stockholders ratified RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Proposal 2 (Auditor ratification) received 20,781,403 votes in favor.
Apyx Medical Corp filed an 8-K to announce its second quarter 2024 results for the period ended June 30, 2024. The filing serves as a formal announcement of the earnings press release issued on August 8, 2024.
📋 Key Facts
- Reporting date: August 8, 2024
- Period covered: Second quarter ended June 30, 2024
- The filing is intended to satisfy Item 2.02 of Form 8-K regarding results of operations and financial condition.
- Earnings press release included as Exhibit 99.1.
Apyx Medical Corp filed an 8-K to announce its quarterly earnings results for the first quarter ended March 31, 2024. The filing serves as a formal mechanism to furnish the press release containing these financial results.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024
- Filing date: May 9, 2024
- The filing includes an earnings press release as Exhibit 99.1
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 of the Exchange Act.
Apyx Medical Corp announced a leadership transition in its Board of Directors involving the retirement of Chairman Andrew Makrides and the appointment of Stavros G. Vizirgianakis as the new Chairman. The change is accompanied by a negotiated letter agreement including standstill provisions and an agreement to identify an additional director.
🚩 Red Flags
- Negotiated standstill agreement suggests the appointment may have been part of a settlement or negotiation with an activist/significant investor.
- The requirement for 'net long ownership of 5% or more' to trigger additional board seats indicates significant influence from the new Chairman.
📋 Key Facts
- Andrew Makrides retired as Director and Chairman of the Board effective May 7, 2024; retirement was not due to any disagreement with the company.
- Stavros G. Vizirgianakis appointed as Director and Chairman of the Board to fill the vacancy.
- The appointment includes a standstill agreement for Mr. Vizirgianakis until the close of the 2025 Annual Meeting of Stockholders.
- Standstill terms include a cap on beneficial ownership at 9.9% and restrictions on soliciting proxies or nominating directors.
- Agreement contains a provision to identify an 'Additional Director' if certain conditions (6-month continuous service and 5% net long ownership) are met by Mr. Vizirgianakis.
Apyx Medical Corp filed an 8-K to announce its results of operations for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal mechanism to furnish earnings press release information under Item 2.02.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: March 21, 2024.
- The filing includes an earnings press release as Exhibit 99.1.
Apyx Medical Corp announced that its Renuvion technology will be featured in three educational sessions at the American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting.
📋 Key Facts
- The company's Renuvion technology is being showcased at a major industry event: the American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting.
- The event takes place in New Orleans, LA from February 22 – 24, 2024.
- The announcement was made via press release on February 21, 2024.
Apyx Medical Corp issued an 8-K to announce the publication of a peer-reviewed clinical study regarding the safety of its Renuvion® product in subcutaneous soft tissue contraction following liposuction.
📋 Key Facts
- Publication of a peer-reviewed clinical publication released on January 22, 2024.
- The study evaluates the safety of Renuvion® for contracting subcutaneous soft tissue after liposuction across multiple body areas.
Apyx Medical Corp issued an 8-K to furnish preliminary revenue results for the fourth quarter and full year ended December 31, 2023. The filing serves as a placeholder for the upcoming earnings release.
📋 Key Facts
- Reported date: January 8, 2024
- Content: Preliminary revenue results for Q4 and FY 2023
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.